Here are the S-1 registration statements from Azitra Inc (AZTR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow AZTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AZTR filings page.
Azitra, Inc. is registering 255,699,381 shares of common stock for resale by existing investors. These shares come from the conversion of 10,485 shares of Series A preferred stock into 85,223,129 conversion shares and the potential exercise of Series B and C warrants for 170,466,252 warrant shares, including related pre-funded warrants. Azitra is not selling shares in this offering and will not receive proceeds from stockholder resales, though full cash exercise of the warrants could bring in approximately $21 million. Common stock outstanding was 16,192,438 shares as of May 19, 2026, and would increase to 271,865,819 shares if all preferred, warrants and pre-funded warrants are fully exercised. The company reports a going concern warning, limited cash resources, significant potential dilution, and an existing NYSE American listing compliance plan.
Azitra, Inc. is registering 51,812,293 shares of common stock for resale by existing investors, tied mainly to a November 2025 private placement and an April 2025 equity line with Alumni Capital. The shares include stock already issued plus shares underlying November pre-funded warrants, common stock purchase warrants, placement agent warrants, and ELOC warrants. Azitra is not selling shares in this prospectus and will not receive proceeds from investors’ resales, though it may receive cash if the warrants are exercised and if additional ELOC Shares are sold under the purchase agreement. The company is an early-stage biopharmaceutical business developing engineered live biotherapeutics and proteins for precision dermatology, led by pipeline candidates ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor–related rash, and ATR-01 for ichthyosis vulgaris. Azitra reports a going concern warning, working capital of about $0.4 million as of September 30, 2025, and a NYSE American notice for not meeting minimum stockholders’ equity requirements, and expects to need more capital to fund operations.